Tags

Type your tag names separated by a space and hit enter

Rimegepant: First Approval.
Drugs. 2020 May; 80(7):741-746.D

Abstract

The orally disintegrating tablet (ODT) formulation of rimegepant (NURTEC ODT®) is a small molecule, highly-selective, calcitonin gene-related peptide antagonist that was developed by Biohaven Pharmaceutical Holding Company Ltd as an acute treatment for migraine. A conventional tablet formulation of the drug is being investigated for the acute treatment (under FDA review in the USA) and prevention of migraine and the treatment of refractory trigeminal neuralgia. In February 2020, rimegepant ODT received its first global approval in the USA for the acute treatment of migraine (± aura) in adults. This article summarizes the milestones in the development of rimegepant leading to its first global approval for acute treatment of migraine (± aura) in adults.

Authors+Show Affiliations

Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32270407

Citation

Scott, Lesley J.. "Rimegepant: First Approval." Drugs, vol. 80, no. 7, 2020, pp. 741-746.
Scott LJ. Rimegepant: First Approval. Drugs. 2020;80(7):741-746.
Scott, L. J. (2020). Rimegepant: First Approval. Drugs, 80(7), 741-746. https://doi.org/10.1007/s40265-020-01301-3
Scott LJ. Rimegepant: First Approval. Drugs. 2020;80(7):741-746. PubMed PMID: 32270407.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rimegepant: First Approval. A1 - Scott,Lesley J, PY - 2020/4/10/pubmed PY - 2020/4/10/medline PY - 2020/4/10/entrez SP - 741 EP - 746 JF - Drugs JO - Drugs VL - 80 IS - 7 N2 - The orally disintegrating tablet (ODT) formulation of rimegepant (NURTEC ODT®) is a small molecule, highly-selective, calcitonin gene-related peptide antagonist that was developed by Biohaven Pharmaceutical Holding Company Ltd as an acute treatment for migraine. A conventional tablet formulation of the drug is being investigated for the acute treatment (under FDA review in the USA) and prevention of migraine and the treatment of refractory trigeminal neuralgia. In February 2020, rimegepant ODT received its first global approval in the USA for the acute treatment of migraine (± aura) in adults. This article summarizes the milestones in the development of rimegepant leading to its first global approval for acute treatment of migraine (± aura) in adults. SN - 1179-1950 UR - https://www.unboundmedicine.com/medline/citation/32270407/Rimegepant:_First_Approval L2 - https://dx.doi.org/10.1007/s40265-020-01301-3 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.